| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Departments of Neurology and Neuroscience (Dr. Uhl), Pathology (Dr. Hedreen), and Pathology, Neurology, and Neuroscience (Dr. Price), Neuropathology Laboratory, The Johns Hopkins University School of Medicine, Baltimore, MD; and the Department of Neurology and Howard Hughes Neuroscience Group (Dr. Uhl), Massarhusetts General Hospital. Boston. MA.
Decreased numbers of pigmented neurons of the dopaminer-gic nigrostriatal system are the most striking pathology in the brains of individuals with Parkinson's disease (PD), but it is clear that neurons in the locus ceruleus, vagal nuclei, and nucleus basalis of Meynert are also affected in this disease. Because neurochemical evidence suggested that the mesolimbic dopaminergic system originating in the ventral tegmental area (VTA) may also be involved, the present study was designed to evaluate the mesolimbic dopamine system in PD by counting pigmented neurons in the VTA contralateral to therapeutic lesions placed in the basal ganglia or thalamus. In PD, VTA neurons were depleted to 36 to 55% of control values. Moreover, the VTA showed excessive free pigment, a marker for death of pigmented neurons. These changes may be important in disorders of movement or mentation occurring in PD.
Address correspondence and reprint requests to Dr. Uhl, Wellman 409, The Massachusetts General Hospildl, Fruit St., Boston, MA 02114.
Supported by grants from the US Public Health Servire (NIH AG 03359. NS 07179. and NS 10560). the American Parkinson Disease Association, and the McKnight Foundation.
Accepted for publication duly 22, 1984
This article has been cited by other articles:
|
|
 |
|
  S. Papapetropoulos Regional Alpha-Synuclein Aggregation, Dopaminergic Dysregulation, and the Development of Drug-Related Visual Hallucinations in Parkinson's Disease J Neuropsychiatry Clin Neurosci, May 1, 2006; 18(2): 149 - 157. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H Sienkiewicz-Jarosz, A Scinska, W Kuran, D Ryglewicz, A Rogowski, E Wrobel, A Korkosz, A Kukwa, W Kostowski, and P Bienkowski Taste responses in patients with Parkinson's disease J. Neurol. Neurosurg. Psychiatry, January 1, 2005; 76(1): 40 - 46. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Grimm, A. Mueller, F. Hefti, and A. Rosenthal Molecular basis for catecholaminergic neuron diversity PNAS, September 21, 2004; 101(38): 13891 - 13896. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Ouchi, T. Kanno, H. Okada, E. Yoshikawa, M. Futatsubashi, S. Nobezawa, T. Torizuka, and K. Tanaka Changes in dopamine availability in the nigrostriatal and mesocortical dopaminergic systems by gait in Parkinson's disease Brain, April 1, 2001; 124(4): 784 - 792. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. B. Saper `Like a thief in the night' : the selectivity of degeneration in Parkinson's disease Brain, August 1, 1999; 122(8): 1401 - 1402. [Full Text] [PDF]
|
|
|
|
 |
|
 W. J.G. Hoogendijk, I.E. C. Sommer, G. Tissingh, D. J.H. Deeg, and E.Ch. Wolters Depression in Parkinson's Disease: The Impact of Symptom Overlap on Prevalence Psychosomatics, October 1, 1998; 39(5): 416 - 421. [Abstract] [Full Text]
|
|
|
|
|
|
T. J Counihan and J. B Penney Jr Regional dopamine transporter gene expression in the substantia nigra from control and Parkinson's disease brains J. Neurol. Neurosurg. Psychiatry, August 1, 1998; 65(2): 164 - 169. [Abstract] [Full Text]
|
|
|
|
|
|
N. Takahashi, L. L. Miner, I. Sora, H. Ujike, R. S. Revay, V. Kostic, V. Jackson-Lewis, S. Przedborski, and G. R. Uhl VMAT2 knockout mice: Heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity PNAS, September 2, 1997; 94(18): 9938 - 9943. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
